Combination of ultrasound and mammography detects additional cancers in Japanese women

Adding ultrasound to standard mammography tests in breast screening could result in improved rates of detection for breast cancer in women in Japan, according to a new study, published in The Lancet.

Researchers led by Professor Noriaki Ohuchi, from Tohoku University Graduate School of Medicine, in Miyagi, Japan, recruited more than 70000 women in Japan aged between 40 and 49 to participate in the J-START trial. Half were offered the usual mammography screening, and half were offered ultrasound testing in addition to mammography, with two screening sessions taking place over two years.

The results show that ultrasound combined with mammography resulted in correct identifications of cancer in more than 9 out of 10 cases (91% sensitivity), whereas for women given mammography alone, just over three quarters of tests correctly identified breast cancer (77% sensitivity).

Breast cancer already affects large numbers of women in Europe and the US, but rates are increasing rapidly in Japan and other Asian countries. Early detection and treatment is critically important for reducing deaths from the disease, and many developed countries have implemented mammography screening programmes for the women who are most at risk.

In Asia, breast cancer tends to present at an earlier age than in Europe or the US, and Asian women have denser breast tissue, both of which are known to reduce the accuracy of mammography. As such, detection using standard mammography screening based on European and US practice might miss cases of breast cancer in Asian countries.

In addition to accurately detecting more cases of breast cancer, adding ultrasound to mammography detected more cancers at an early stage (144 cancers at stage 0 or 1, compared to 79 cancers at stage 0 or 1 detected by mammography alone). The addition of ultrasound also resulted in fewer interval cancers (which appear after a negative test result between scheduled rounds of screening), leading researchers to conclude that adding ultrasound to mammography screening detected additional cancers, compared to mammography alone.

While previous studies have suggested that the addition of ultrasound might lead to an excessively high rate of ‘false positive’ results (where screening results falsely indicate that a cancer is present), these results suggest that the difference in false positive rates between the two testing protocols was small, and could be further reduced by ensuring that mammography and ultrasound test results are analysed together.

“Our results suggest that adding ultrasound to mammography results in more accurate screening results for women in Japan, which could ultimately lead to improved treatment and reduced deaths from the disease,” says Professor Ohuchi. “Further work will now be needed to see if these results can be extended to other countries in Asia. In addition, long-term follow-up of these results will determine whether including ultrasound tests in breast cancer screening ultimately affects the likelihood of successful treatment and survival, as we would expect.”

In a linked Comment, Martin Yaffe and Roberta Jong from the University of Toronto, Canada, write:

We believe that J-START7 is an important trial for several reasons. It is the first randomised trial of population screening with ultrasonography, and was done in asymptomatic women at average risk, who were not preselected on the basis of other imaging findings. Earlier studies, most of which were done in the USA, involved women at moderate or high risk of breast cancer…Furthermore, the J-START trial was done in relatively young women. Despite evidence of mammography screening effectively reducing mortality in women in their 40s, this method is seldom recommended or provided for women younger than 50 years. Definitive evidence of whether ultrasonography screening of women from age 40 years can further reduce breast cancer mortality could be an important step.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Mursla Bio announces promising results for EvoLiver test in liver cancer detection